Project Grant R01CA290700
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$565K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Sacramento, CA 95817, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $411,400 to Northwestern University to develop and characterize a cell culture model of Kaposi's sarcoma (KS). The primary objective is to identify KSHV-induced cellular genes that promote the loss of contact inhibition of proliferation (CIP) in KSHV-infected lymphatic endothelial cells (KLECs), which are believed to be the cell of origin for KS tumors. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The $188,169 grant, awarded on March 10, 2025, will fund proof-of-concept studies to evaluate the biological activity and efficacy of this gene therapy approach in killing cancer cells through in vitro assays...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,349,322 to the University of Pittsburgh to investigate the role of the METTL16 protein and the methionine/S-adenosylmethionine (SAM) cycle in Kaposi's sarcoma-associated herpesvirus (KSHV) infection. The research aims to identify KSHV-regulated METTL16-specific methylation marks, delineate how the SAM cycle regulates KSHV latent and lytic infections, and determine how KSHV...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $185,513 to the University of Arkansas for Medical Sciences (UAMS) to develop targeted protein degraders, known as OPROTACs, that aim to interfere with the survival of cells infected by the Kaposi's sarcoma-associated herpesvirus (KSHV). KSHV is the causative agent of several cancers, including Kaposi's sarcoma and...
The National Cancer Institute (NCI) awarded a 5-year, $767,691 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research aimed at defining critical antigenic targets and specific epitopes that induce KSHV-neutralizing antibodies, and evaluating the ability of these antibodies to protect against KSHV infection in a small animal model. The goal is to inform the design and development of a KSHV vaccine to prevent...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to understand the mechanisms by which the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) manipulates cellular metabolism to facilitate viral replication and tumorigenesis. The $1,337,014 award, with a project period from Sep 1, 2024 to May 31, 2029, will be conducted by the Cleveland Clinic Lerner...
This $435,506 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand how the Epstein-Barr virus (EBV) contributes to the development and progression of various types of non-Hodgkin's lymphoma, including those associated with HIV infection. The University of North Carolina at Chapel Hill will conduct this research over a 5-year period from September 2024 to August 2029. The key objectives are to: 1) identify how EBV...
This federal Project Grant award of $544,768.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research aimed at understanding the mechanisms of papillomavirus tumor regression through inhibition of the MEK signaling pathway. The primary awardee, the University of New Mexico Health Sciences Center, will leverage single-cell and spatial transcriptomics, along with functional assays, to investigate how MEK inhibition alters intrinsic keratinocyte antiviral...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $1,104,864 to the University of California, Davis to conduct research on the molecular mechanisms of homologous recombination and chromosome maintenance. The research aims to understand how defects in the proteins involved in DNA pairing, including BRCA2 and the RAD51 paralogs, lead to chromosomal instability and cancer predisposition. The research will use biochemical...
This federal Project Grant award of $666,567 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify the transcriptional regulators that control the function of human natural killer (NK) cells during viral infections. The key objectives are to determine the mechanisms by which the transcription factor MEF2C regulates human NK cell cytotoxicity, proliferation, and antiviral...